Formulation and Encapsulation Services

A therapeutic that cannot reach its target in an active form will fail regardless of intrinsic potency. This is the central problem for nucleic acid therapeutics in particular, since unprotected siRNA, microRNA, mRNA, and plasmid DNA are degraded rapidly in circulation, cleared before reaching most tissues, and do not cross cell membranes unaided. Formulation is not a finishing step applied to a completed molecule; it determines whether the molecule has any chance of working.

Altogen Labs provides liposome encapsulation for siRNA, microRNA, DNA, and proteins, siRNA-specific liposome encapsulation, nanoparticle encapsulation and formulation, and in vivo delivery with tissue targeting. Formulated material moves directly into delivery, biodistribution, and efficacy studies within the same facility.

Altogen Labs has developed transfection and delivery reagents commercially and has supported nucleic acid delivery programs for pharmaceutical and biotechnology clients, with company scientists contributing to the peer-reviewed literature and to patent filings in this area. That background means formulation questions are approached from delivery experience rather than from a catalog of standard compositions.

Encapsulation approaches

Liposomal encapsulation encloses the payload within a lipid bilayer vesicle, protecting it from nuclease degradation, extending circulation time, and providing a route across the cell membrane. Composition governs behavior: lipid selection, the presence and density of polyethylene glycol on the surface, and surface charge together determine circulation half-life, tissue distribution, and clearance route. Altogen Labs formulates to the payload and intended target tissue rather than applying a single standard composition.

Nanoparticle formulation covers lipid nanoparticle and polymeric systems and is selected where payload characteristics, required loading, or stability are not well served by a conventional liposome. Particle size, polydispersity, surface charge, encapsulation efficiency, and payload integrity are characterized for each preparation, since these parameters determine biodistribution and are the first thing to examine when an in vivo result disappoints.

Microfluidic production is used where reproducible particle size distribution matters, offering tighter control of mixing conditions than bulk methods.

To discuss a formulation requirement, request a quote.

From formulation to in vivo result

The advantage of formulating and testing in one facility is that a disappointing in vivo result can be diagnosed rather than merely observed. When a formulated nucleic acid fails to produce target knockdown in tissue, the cause may be particle instability, clearance before reaching the target, failure to enter cells, endosomal entrapment, or insufficient potency of the payload itself. Distinguishing between these requires access to both the characterization data and the in vivo material, and is substantially harder when the two were generated by different organizations.

Altogen Labs measures oligonucleotide accumulation in target and clearance tissues, target transcript knockdown by quantitative PCR, and target protein reduction by Western blot and ELISA, within the same study that assessed the formulation. Tissue distribution across the organ panel relevant to the delivery route establishes whether the formulation reached the intended compartment and what proportion was diverted elsewhere, and can be followed non-invasively through in vivo imaging and biodistribution studies.

Applied examples

Hepatic siRNA delivery. An siRNA targeting a hepatocyte-expressed gene is encapsulated, administered intravenously, and assessed at multiple timepoints for oligonucleotide accumulation in liver, target transcript knockdown by qPCR, and target protein reduction by Western blot, with kidney and spleen included to quantify off-target distribution.

Formulation comparison. Two liposomal compositions differing in polyethylene glycol density are administered in parallel, and circulation time and liver-to-spleen distribution ratio are compared, identifying which composition to carry into the efficacy study before any efficacy animals are committed.

CNS-directed delivery. A formulation intended for central nervous system exposure is evaluated for brain accumulation against a peripheral organ panel, with blood-brain barrier model work used to establish whether the limiting step is barrier penetration or systemic clearance.

Applications

Formulation services support RNA interference programs, where encapsulation is a prerequisite for systemic in vivo work; messenger RNA and plasmid DNA delivery; protein and peptide delivery where stability or membrane permeability limits activity; and small molecule formulation where solubility or exposure is the limiting factor. Programs targeting the central nervous system are developed against the blood-brain barrier constraint from the outset rather than adapting a systemic formulation afterward.

Material scope and characterization standards

Formulation composition, characterization panel, acceptance criteria, and release specification are defined per project, and each batch is characterized before release into a study rather than assumed equivalent to a previous preparation. Altogen Labs produces research-grade material for preclinical use; clinical or commercial scale manufacture is not offered, and formulations are not represented as GMP material. All in vivo procedures are conducted under active IACUC protocols, and GLP standards are applied where a study is formally designated as GLP.

Send payload and target tissue details, or request a quote.